News

€6m to fight a fatal disease
Enlarge image

BusinessSwitzerlandEU

€6m to fight a fatal disease

16.10.2012 - The European Commission gives €6m to a research consortium tackling a severe immune system disorder. „FIGHT HLH“ is led by Swiss Novimmune.

The European Commission wants to dismantle a malicious disease. By spending €6m of FP7 money for research into hemophagocytic lymphohistiocytosis (HLH), it wants to advance knowledge about possible treatment options about this orphan disease. The awardee is a consortium of institutions named FIGHT HLH. Among the institutions are Hospitals in Florence and Rome and Lonza Biologics plc. The consortium leader, however, is based in Switzerland. Novimmune SA from Geneva is the originator of the treatment option in question: NI-0501. This fully human monoclonal antibody is a potent inhibitor of the cytokine IFNγ, Cristina de Min, the company’s Chief Medical Officer, stresses the aim of the collaboration: „The programme is designed to give a clear readout on the ability of the drug to affect disease course.“ Novimmune CEO Jack Barbut adds that he is „delighted to have been selected by the European Commission for such a prestigious grant.“

HLH is caused by an impairment of cytotoxic T cell function that triggers an anomalous activation of the immune system. This activation stems mainly from an dramatic increase in IFNγ levels. NI-0501 targets IFNγ. Novimmune tested the drug in Phase I clinical trials successfully for safety and also demonstrated in animal studies that clearing excess IFNγ with the antibody reverses organ pathology and re-establishes key clinical parameters.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/eur6m-to-fight-a-fatal-disease.html

Clinical TrialsEUFrancePortugal

31.05.2016 The European Medicines Agency (EMA) means to increase first-in-man trial safety. Following the death of a volunteer in a Phase I trial earlier this year, the European Medicines Agency has started a review of the guidelines for first-in-man studies.

AwardFinlandEU

27.05.2016 The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • THERAMETRICS (CH)0.03 CHF50.00%
  • SCANCELL HOLDINGS (UK)19.38 GBP14.81%

FLOP

  • NORDIC NANOVECTOR (N)25.50 NOK-5.90%
  • BIONOR PHARMA (N)0.64 NOK-5.88%
  • FORMYCON (D)20.42 EUR-5.42%

TOP

  • GALAPAGOS (B)51.78 EUR30.5%
  • NICOX (F)11.00 EUR28.7%
  • GENMAB (DK)1208.00 DKK25.4%

FLOP

  • MOBERG PHARMA (S)38.40 SEK-21.0%
  • BIONOR PHARMA (N)0.64 NOK-19.0%
  • 4SC (D)2.70 EUR-18.2%

TOP

  • KARO BIO (S)29.90 SEK1880.1%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)11.00 EUR491.4%

FLOP

  • BB BIOTECH (D)44.62 EUR-84.5%
  • BIOTEST (D)17.75 EUR-77.4%
  • EVOCUTIS (UK)0.05 GBP-77.3%

No liability assumed, Date: 31.05.2016